ArticleTransfusion medicine (Oxford, England)2026
Determining a safe pre-transfusion protocol for multiple myeloma patients on anti-CD38 treatment.
Article in Transfusion medicine (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative considerations for patients with multiple myeloma.European journal of anaesthesiology and intensive care · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDaratumumab is a monoclonal antibody therapy used to treat multiple myeloma. It has introduced challenges for blood transfusion laboratories to provide safe red cells for transfusion due to the cross-reactivity of daratumumab with red cell surface antigens on antibody screening cells, resulting in panreactivity and preventing the exclusion of alloantibodies. NHS Lothian transfusion protocol for patients on daratumumab involves pre-daratumumab extended patient phenotyping of significant RBC antigens and transfusion of RhD (CcEe) and K phenotype matched Red Cell Concentrate (RCC) without performing any pre-transfusion antibody screening.
methodsTo determine alloimmunisation rates following the current protocol the laboratory information management system (LIMS) was interrogated to determine if patients previously on daratumumab had developed antibodies in response to transfused RCCs. Grifols sCD38 was used to neutralise daratumumab in transfused patients. sCD38 was used to (1) assess alloimmunisation rates in patients on treatment (2) assess how it could be applied in a routine pre transfusion testing protocol.
resultsSince 2018, 185 patients started daratumumab therapy in Lothian. There was a record of RCC transfusion in 102 patients. From the LIMS, negative antibody screens were recorded in 21 patients post-daratumumab treatment. No alloimmunisation was detected from 34 transfused patients still on daratumumab.
conclusionLow alloimmunisation suggests NHS Lothian protocol for transfusion of daratumumab patients is safe. Extended phenotyping of patients pre-treatment may be extensive and unnecessary due to the low alloimmunisation rate. Implementation of sCD38 reagent into pre-transfusion testing can reduce extensive pre-treatment testing and improve the safety of transfusion by exclusion of alloantibodies in daratumumab patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.